Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -40.05 | — | — | — | — | — | 13.22 | — | — | — | — | — | — | 6.13 | 48.75 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.56 | 145.80 | 1.33 | 1.09 | 1.41 | 1.16 | 1.38 | 0.79 | 0.49 | 0.55 | 0.70 | 0.68 | 0.67 | 0.49 | 0.77 | 0.89 | 0.76 | 0.74 | 0.93 | 2.08 | 1.24 |
| — | +12511.3% | -3.4% | +37.2% | +184.2% | +110.9% | +97.7% | +17.1% | -26.0% | +11.6% | -9.6% | -23.7% | -12.5% | -33.8% | -16.8% | -57.3% | -38.1% | -37.6% | -15.4% | +92.2% | -5.9% | |
| P/B Ratio | 4.64 | 5.68 | 2.28 | 2.43 | 1.81 | 1.81 | 2.28 | 1.47 | 0.74 | 0.83 | 0.87 | 0.87 | 0.76 | 0.58 | 0.79 | 0.90 | 0.91 | 0.78 | 1.02 | 1.62 | 0.85 |
| — | +213.4% | +0.2% | +65.1% | +146.0% | +118.2% | +161.5% | +69.5% | -2.9% | +42.9% | +10.4% | -3.8% | -16.5% | -25.5% | -22.3% | -44.5% | +6.0% | -13.5% | +3.1% | +71.5% | -15.8% | |
| P/FCF | 23.58 | — | 31.41 | — | 75.28 | 15.33 | 4.19 | 4.41 | 8.71 | — | — | 6.65 | 5.91 | 1.04 | — | 4.06 | 3.61 | 3.54 | — | 9.19 | — |
| — | — | +649.5% | — | +764.3% | — | — | -33.7% | +47.4% | — | — | +63.9% | +63.7% | -70.6% | — | -55.9% | — | -11.7% | — | -46.7% | — | |
| EV / EBITDA | 45.21 | — | — | — | — | 19.41 | 5.74 | — | — | 16.23 | — | — | — | 3.63 | — | — | 6.62 | — | 31.07 | — | — |
| — | — | — | — | — | +19.6% | — | — | — | +346.6% | — | — | — | — | — | — | — | — | +194.6% | — | — | |
| EV / EBIT | — | — | — | — | — | — | 10.56 | — | — | — | — | — | — | 5.20 | 22.46 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.0% | 77.5% | 78.8% | 83.6% | 88.1% | 81.4% | 87.8% | 81.1% | 85.4% | 82.6% | 81.5% | 83.6% | 82.5% | 86.0% | 86.4% | 71.0% | 80.5% | 80.3% | 80.2% | 60.0% | 83.5% |
| — | -4.8% | -10.3% | +3.2% | +3.1% | -1.4% | +7.8% | -3.1% | +3.6% | -4.0% | -5.8% | +17.9% | +2.5% | +7.2% | +7.8% | +18.2% | -3.6% | -0.6% | +4.1% | -23.0% | +8.7% | |
| Operating Margin | -6.3% | -1898.7% | -34.3% | -10.0% | -23.7% | -6.9% | 11.0% | -17.7% | -18.6% | -10.4% | -22.0% | -66.1% | -18.5% | 0.2% | -16.6% | -25.0% | -2.5% | -17.9% | -11.6% | -52.3% | -19.4% |
| — | -27427.9% | -410.7% | +43.2% | -27.1% | +33.8% | +150.1% | +73.3% | -0.8% | -5066.4% | -32.5% | -164.6% | -631.9% | +101.2% | -43.6% | +52.3% | +86.9% | -13.1% | -275.7% | -207.6% | -48.2% | |
| Net Margin | -6.4% | -2472.5% | -34.4% | -10.3% | -23.4% | -6.8% | 10.7% | -18.2% | -17.0% | -11.0% | -22.9% | -67.3% | -10.4% | 8.0% | 2.1% | -26.8% | -3.6% | -13.0% | -12.4% | -46.2% | -13.1% |
| — | -36073.4% | -420.2% | +43.4% | -37.7% | +38.0% | +146.9% | +72.9% | -63.4% | -237.6% | -1199.3% | -151.6% | -190.6% | +161.8% | +116.8% | +42.2% | +72.6% | -195.6% | -883.0% | -437.0% | -151.0% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -12.0% | -21.4% | -13.7% | -5.6% | -7.3% | -2.6% | 4.9% | -8.1% | -6.1% | -4.1% | -6.9% | -19.4% | -2.9% | 2.4% | 0.5% | -6.6% | -1.1% | -3.3% | -3.3% | -8.6% | -2.2% |
| — | -710.3% | -377.1% | +30.8% | -18.7% | +35.2% | +171.7% | +58.2% | -111.2% | -270.5% | -1392.0% | -195.8% | -175.2% | +171.7% | +116.1% | +24.0% | +52.9% | -228.7% | -1033.4% | -362.1% | -123.2% | |
| ROA | -3.7% | -6.1% | -4.2% | -2.0% | -2.9% | -1.1% | 1.7% | -2.5% | -2.0% | -1.4% | -2.4% | -7.4% | -1.2% | 1.0% | 0.2% | -2.7% | -0.4% | -1.4% | -1.5% | -4.5% | -1.2% |
| — | -472.1% | -345.8% | +20.9% | -45.9% | +20.8% | +172.5% | +66.3% | -67.9% | -239.1% | -1231.4% | -179.4% | -165.7% | +169.1% | +113.8% | +40.6% | +62.7% | -204.7% | -969.9% | -387.1% | -140.3% | |
| ROIC | -8.6% | -12.4% | -10.8% | -4.7% | -6.9% | -2.5% | 4.0% | -5.2% | -4.3% | -2.5% | -4.7% | -14.2% | -3.8% | 0.0% | -3.0% | -4.6% | -0.6% | -3.3% | -2.6% | -9.5% | -3.1% |
| — | -403.2% | -371.0% | +9.5% | -59.3% | +3.3% | +184.4% | +63.8% | -13.3% | -5880.2% | -58.8% | -208.3% | -582.6% | +101.3% | -16.0% | +51.4% | +82.1% | -16.0% | -320.6% | -197.1% | -40.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.41 | 0.28 | 0.47 | 0.41 | 0.40 | 0.37 | 0.37 | 0.91 | 0.88 | 0.83 | 0.80 | 0.63 | 0.52 | 0.51 | 0.58 | 0.58 | 0.47 | 0.50 | 0.51 | 0.38 | 0.35 |
| — | -26.2% | +28.3% | -54.5% | -54.8% | -54.9% | -53.7% | +44.9% | +67.9% | +61.1% | +38.1% | +8.1% | +12.3% | +3.3% | +13.1% | +54.6% | +33.1% | +52.7% | +41.9% | -8.3% | -13.3% | |
| Debt / EBITDA | 4.08 | — | — | — | — | 18.09 | 4.00 | — | — | 54.20 | — | — | — | 12.47 | — | — | 14.28 | — | 57.47 | — | — |
| — | — | — | — | — | -66.6% | — | — | — | +334.8% | — | — | — | — | — | — | — | — | +208.4% | — | — | |
| Current Ratio | 1.01 | 0.96 | 0.95 | 1.01 | 1.23 | 1.30 | 1.25 | 1.15 | 1.13 | 1.44 | 1.37 | 1.28 | 1.53 | 1.62 | 1.70 | 1.60 | 1.94 | 1.80 | 1.85 | 2.37 | 2.63 |
| — | -26.6% | -23.9% | -12.5% | +8.7% | -9.4% | -8.8% | -9.7% | -25.8% | -11.3% | -19.6% | -20.5% | -21.3% | -10.2% | -7.7% | -32.3% | -26.2% | -27.9% | -14.6% | +21.7% | +28.8% | |
| Quick Ratio | 0.84 | 0.96 | 0.79 | 0.84 | 1.11 | 1.17 | 1.09 | 1.03 | 0.99 | 1.26 | 1.21 | 1.11 | 1.21 | 1.21 | 1.31 | 1.26 | 1.52 | 1.42 | 1.44 | 1.93 | 2.06 |
| — | -18.2% | -27.2% | -18.2% | +12.4% | -7.6% | -9.8% | -7.7% | -18.4% | +4.0% | -7.8% | -11.8% | -20.4% | -14.2% | -9.4% | -34.8% | -26.1% | -27.8% | -16.2% | +26.1% | +27.0% | |
| Interest Coverage | -4.69 | -4365.28 | -35.55 | -11.33 | -16.72 | -5.66 | 8.65 | -7.77 | -10.10 | -7.64 | -14.95 | -34.11 | -8.60 | 5.51 | 1.96 | -12.44 | -1.79 | -8.87 | -10.67 | -156.75 | -77.72 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CPIX stock.
Cumberland Pharmaceuticals Inc.'s current P/E is -40.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Cumberland Pharmaceuticals Inc.'s current operating margin is -6.3%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Cumberland Pharmaceuticals Inc.'s business trajectory between earnings reports.